A bivalent CMV vaccine formulated with human compatible TLR9 agonist CpG1018 elicits potent cellular and humoral immunity in HLA expressing mice

There is now convincing evidence that the successful development of an effective CMV vaccine will require improved formulation and adjuvant selection that is capable of inducing both humoral and cellular immune responses. Here, we have designed a novel bivalent subunit vaccine formulation based on C...

Descripción completa

Detalles Bibliográficos
Autores principales: Dasari, Vijayendra, Beckett, Kirrilee, Horsefield, Shane, Ambalathingal, George, Khanna, Rajiv
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9223316/
https://www.ncbi.nlm.nih.gov/pubmed/35737741
http://dx.doi.org/10.1371/journal.ppat.1010403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9223316/
https://www.ncbi.nlm.nih.gov/pubmed/35737741
http://dx.doi.org/10.1371/journal.ppat.1010403

Ejemplares similares